MedWatch

Candidate drug gives months to cancer patients

Fresh data from two international pharmaceutical companies show that a phase III candidate drug against an aggressive type of breast cancer can extend the lives of patients by several months.

Foto: Roche/PR

The Swizz company Roche and its subsidiary Genentech now have the results of a phase III trial with the candidate drug trastuzumab emtansine.

The study tests the effect of the candidate on the aggressive type of breast cancer known as HER2-positive metastatic breast cancer (MBC). Data shows that the risk of dying was reduced by 32 % for patients treated with trastuzumab emtansine, compared with those that received standard treatment in the form of a combination of the drugs lapatinib and xeloda.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier